Market Analysis: Nuclear Energy Boom, Gene Editing Struggles, and Meme Stock Opportunities in a Volatile Macro Environment

As we navigate the complex market landscape of mid-2025, several key investment themes are emerging. OKLO's meteoric 643% rise showcases the nuclear energy renaissance, while NTLA's struggles highlight biotech sector challenges. Meanwhile, OPEN's recent 400% meme stock rally presents both opportunity and risk. Against this backdrop, macroeconomic uncertainty from tariff policies and Fed positioning continues to drive market volatility.

---

OKLO: The Nuclear Renaissance in Full Swing

Performance Highlights

OKLO has delivered extraordinary returns with a 643.29% increase over the past year and a 20.93% gain just this month. The stock recently surged to an all-time high of $73.55 on June 16, 2025, trading around $67 as of our analysis.

Strategic Positioning

The company's momentum is backed by solid fundamentals:

• Active customer pipeline exceeds 14GW, with an estimate to deploy 5GW of capacity through 2035
• The data center opportunity alone represents a total addressable market in the tens of billions of dollars annually
• Recent strategic partnerships, including collaborations with Liberty Energy for integrated energy solutions

Trading Outlook

Wall Street analysts maintain a Strong Buy consensus with an average price target of $60.29, though the stock currently trades above most targets. Technical analysis suggests potential for 146% upside over the next 3 months, but traders should be prepared for high volatility given the stock's 2.44 beta coefficient.

Trading Strategy: Consider taking profits on strength while maintaining core positions for the long-term nuclear energy theme.

---

NTLA: Gene Editing's Growing Pains

Performance Reality Check

NTLA has declined 51.96% over the past year, trading around $12 after reaching highs near $28. The stock faces significant headwinds despite maintaining a "Buy" rating from 19 analysts with a $35.11 average price target.

Fundamental Concerns

The company's challenges are multifaceted:

• 2024 losses of $519.02 million, 7.86% higher than 2023
• January 2025 strategic restructuring reduced workforce by 27%
• Ongoing clinical trial risks and regulatory uncertainties

Investment Perspective

Despite near-term challenges, analysts forecast significant revenue growth of 109.12% annually as clinical programs advance. The company is expected to achieve profitability by 2027 with projected EPS of $1.34.

Trading Strategy: NTLA remains a high-risk, high-reward biotech play. Consider dollar-cost averaging for long-term positions rather than attempting to time the bottom.

---

AGNC: Mortgage REIT Stability in Uncertain Times

Recent Earnings Performance

AGNC reported Q1 2025 results with $0.44 net spread and dollar roll income per common share and a 2.4% economic return on tangible common equity. The company maintains $8.25 tangible net book value per common share as of March 31, 2025.

Market Response and Outlook

Analysts maintain mixed sentiment with 3 Buy ratings and 5 Hold ratings, and an average price target of $9.50. The stock's current trading near target levels suggests fair valuation.

Dividend Sustainability

AGNC continues its monthly dividend of $0.12 per share for July 2025, providing attractive income despite interest rate headwinds. Management noted favorable positioning with 63% of tangible equity in cash and unencumbered Agency MBS.

Trading Strategy: AGNC offers steady dividend income with moderate capital appreciation potential. Suitable for income-focused portfolios seeking monthly distributions.

---

OPEN: The Meme Stock Phenomenon Returns

The Rally That Shocked Markets

OPEN exploded over 400% in July alone, surging from under $1 to peaks near $5 before settling around $2.88. Trading volumes exploded with 1.9 billion shares exchanging hands on July 21, more than 1,700% of the three-month average.

Driving Forces Behind the Move

The rally was fueled by several factors:

• Short interest of about 22% of available shares created potential for short covering
• Hedge fund manager Eric Jackson's bullish thesis suggesting the stock could reach $82
• Retail trading activity surge driven by WallStreetBets discussions

Long-Term Potential and LEAPS Strategy

Despite meme stock volatility, OPEN's business model has merit:

• Digital real estate platform with technology-driven home buying/selling
• Comparisons to Carvana's dramatic turnaround story
• Potential beneficiary of housing market normalization

2026-2027 LEAPS Opportunity

Strategic Rationale: The extreme volatility creates attractive LEAPS opportunities for patient investors. Consider:

• 2026 LEAPS Calls: Strike prices between $3-5 offer leveraged exposure to recovery
• 2027 LEAPS Calls: Longer time horizon allows for business model execution
• Risk Management: Position size carefully due to high volatility and execution risk

The housing market normalization expected in 2026-2027 could provide fundamental support for OPEN's business model recovery.

Trading Strategy: Use LEAPS as a speculative allocation (1-2% of portfolio) with defined risk tolerance. The extended time horizon provides runway for both meme stock momentum and fundamental improvement.

---

Macroeconomic Landscape: Navigating Policy Uncertainty

The Tariff Overhang

Current U.S. tariff rates have reached levels not seen since the 1930s, with effective rates now exceeding 15%. Markets experienced significant volatility following President Trump's April 2 tariff announcement, with the S&P 500 nearly entering bear market territory.

Key impacts include:

• Policy uncertainty elevated to record highs, driving market volatility
• Stagflationary risks from higher import costs
• Potential disruption to foreign investment in U.S. Treasury markets

Federal Reserve Policy Dynamics

The Fed remains on hold with markets expecting one rate cut in 2025 and three to four more in 2026. Labor market dynamics remain crucial, with companies cutting hiring plans but not yet implementing significant layoffs.

Market Implications for Trading

The macro environment creates several trading considerations:

1. Sector Rotation Opportunities: Dispersion across stocks, styles, sectors, and countries expected
2. Currency Volatility: USD weakness continuing with 10%+ year-to-date declines
3. Interest Rate Sensitivity: Duration risk remains elevated across asset classes

---

Investment Strategy and Risk Management

Portfolio Positioning Recommendations

Growth Allocation:

• Maintain OKLO positions but consider profit-taking on strength
• NTLA for speculative biotech exposure with careful position sizing

Income Focus:

• AGNC provides steady monthly income with reasonable stability
• Monitor interest rate sensitivity and duration risk

Speculative Plays:

• OPEN LEAPS for 2026-2027 expiration provide asymmetric risk/reward
• Size positions appropriately given high volatility

Risk Management Framework

1. Position Sizing: Limit individual positions to appropriate risk levels
2. Diversification: Balance across sectors and time horizons
3. Volatility Management: Use options strategies to manage downside risk
4. Macro Hedging: Consider Treasury positions for policy uncertainty protection

---

Conclusion: Navigating Opportunity Amid Uncertainty

The current market environment presents both exceptional opportunities and significant risks. OKLO's nuclear energy theme offers compelling long-term growth, while OPEN's meme stock status creates interesting LEAPS opportunities for 2026-2027. NTLA remains a high-risk biotech play requiring patience, and AGNC provides stability through its monthly dividend.

The macroeconomic backdrop of policy uncertainty, tariff concerns, and Fed positioning requires careful navigation. Successful trading in this environment demands disciplined risk management, appropriate position sizing, and maintaining flexibility to adapt to rapidly changing conditions.

Key Takeaway: Focus on asymmetric risk/reward opportunities while maintaining robust risk management. The market's current volatility creates both opportunity and danger – position accordingly.

---

Disclaimer: This analysis is for informational purposes only and should not be considered personalized investment advice. Past performance does not guarantee future results. All investments carry risk of loss. Please consult with a qualified financial advisor before making investment decisions.

Follow SharkWater Trading for more market analysis and trading insights.

What a Wild Ride! Market Update from Shark Water Trading

July 6, 2025

Fellow traders and investors, been offline for a bit but what an absolutely WILD ride this market has been! If you've been following along, you know we've experienced one of the most dramatic market cycles in recent memory, and for those who played it right after Liberation Day, the rewards have been absolutely spectacular.  I've successfully replaced most of my W2 take=home pay with passive income since April.  My dividend payers are AGNC, ORC, YMAX, GIAC and WTPI.  My only Long-term holding at the moment is NTLA.  I continue to hold cash in a MM for the next bumps in the road. I sell PUTS with that and then some intraday covered-calls on NTLA.  Probably done with the covered calls if the new base holds on NTLA.

All-Time Highs After the Storm

The market has been nothing short of a roller coaster, but we're now sitting at all-time highs! By June 27, 2025, the S&P 500 and the NASDAQ closed at all-time highs, with the S&P 500 gaining 0.5%, to close at a record 6,173.07. What makes this even more remarkable is where we came from.

Remember Liberation Day on April 2nd? That was when President Trump announced his sweeping tariff policies, sending shockwaves through the markets. The S&P 500 has tumbled more than 12% in the immediate aftermath, with some calling it one of the worst sell-offs since the pandemic. But here's the thing about markets - they hate uncertainty, and once that uncertainty started to clear, we saw an absolutely explosive recovery.

The Liberation Day Opportunity

For those brave enough to buy during the Liberation Day crash, you've been handsomely rewarded. The S&P 500 has been on a wild round trip: The index shed $9.8 trillion in market value from its previous record on February 19 to its low point on April 8, before recovering all of those losses across the past two and a half months.

The key was recognizing that President Donald Trump said on April 3 regarding his tariffs that events were "going very well", as the "markets are going to boom, the stock is going to boom, the country is going to boom". Smart money listened and positioned accordingly.

Income Powerhouses Leading the Charge

ELF Beauty - The Cosmetics Rocket Ship

Talk about a comeback story! ELF Beauty has been an absolute monster, and anyone who bought the Liberation Day dip is sitting pretty. Full year Fiscal 2025 net sales grew 28%, reflecting another year of industry-leading growth, and the company just announced an agreement to acquire rhode, a fast-growing beauty brand founded by Hailey Bieber for $800 million plus earnouts.

The Street is loving it, with the average price target is $122.00 with a high forecast of $150.00 and a consensus rating of Strong Buy which is based on 13 buy ratings, 3 hold ratings and 0 sell ratings. This isn't just growth - it's profitable, sustainable growth in a defensive consumer staple category.

OKLO - Nuclear Renaissance in Full Swing

Holy smokes, OKLO has been absolutely on fire! Oklo has been on an absolute tear, soaring 559.6% as of this writing over the past year. The nuclear energy renaissance is real, and OKLO is perfectly positioned.

With Sam Altman's OpenAI announcing the Stargate Project in January, investors raced to purchase Oklo, recognizing that the OpenAI plan to develop data center infrastructure could be a potential boon for the company. The data center boom is massive - Research from Dell'Oro Group estimates that global spending is expected to soar from $430 billion on data centers in 2024 to $1.1 trillion by 2029.

Gene Editing Stocks - The Future is Now

The gene editing space has been quietly building momentum, and these names are starting to show serious promise:

CRISPR Therapeutics (CRSP) continues to lead the pack with its revolutionary gene-editing platform. Bank of America has a "buy" rating and $86 price target for CRSP stock, and the company's partnership with Vertex on sickle cell disease treatments could be game-changing.

Intellia Therapeutics (NTLA) has been making waves with its in-vivo gene editing approach. In 2021, Intellia and its partner, Regeneron Pharmaceuticals announced the first clinical data supporting the use of in vivo (in the body) CRISPR-Cas9 gene editing in humans. Bank of America has a "buy" rating and $43 price target for NTLA stock.

Editas Medicine (EDIT) rounds out the big three, focusing on both in-vivo and ex-vivo approaches. The gene editing market is projected to explode, with analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $40.1 billion by 2034.

RKLB - Rocket Lab's Stellar Performance

Rocket Lab has been absolutely crushing it! RKLB stock has risen by 10.03% compared to the previous week, the month change is a 30.22% rise, over the last year Rocket Lab Corporation has showed a 670.19% increase. This space play has been one of our biggest winners.

Rocket Lab reported Q1 2025 revenue of $122.6 million, with $87 million driven by its high-margin Space Systems segment, and the company has $1.067 billion backlog, over 56% convertible within 12 months. With the space economy projected to triple, RKLB is perfectly positioned for the long haul.

The analysts are bullish too, with a median price target of $29.50 (ranging from $19.51 to $45.00) and the overall analyst consensus for RKLB is bullish. Out of 20 Wall Street analysts, 10 rate it as Buy, 4 as Hold, and 0 as Sell.

Rate Cuts on the Horizon

Here's where things get really interesting for the second half of 2025. The Fed is in a tough spot, but the consensus is building for rate cuts. Goldman Sachs economists raised their forecast for Federal Reserve interest rate cuts to three this year and increased the probability of a U.S. recession to 35%.

Asked how the Fed will respond to not only higher prices from tariffs and weakening growth and employment, 65% say the central bank will cut rates. This is huge for income-producing portfolios and growth stocks alike. Lower rates mean higher valuations and more capital flowing into risk assets.

Tariffs and Recession Risks - What's Really Happening

Let's address the elephant in the room. Yes, tariffs are inflationary and create economic headwinds. Goldman expects the average U.S. tariff rate to rise 15 percentage points in 2025, which is significant. However, markets are forward-looking, and much of the tariff impact has already been priced in during the Liberation Day sell-off.

The recession probability has increased - The odds of recession in the next year rose to 53%, up from 22% in January - but here's the key: J.P. Morgan Research has reduced the probability of a U.S. and global recession occurring in 2025 from 60% to 40% as trade tensions have eased and some tariff policies have been walked back.

Even if we do see economic weakness, "We're most likely not going to go into a serious recession, because the Fed can take action to prevent that" as Jim Cramer noted. The Fed has plenty of ammunition to support the economy.

The Bottom Line

We're living through one of the most dynamic and opportunity-rich markets in years. Yes, there's volatility, but that volatility creates opportunity for those willing to do the work and stay disciplined. The companies we've highlighted - ELF, OKLO, the gene editing names, and RKLB - aren't just riding market momentum. They're fundamentally strong businesses positioned in secular growth trends.

For income-focused investors, the combination of potential rate cuts and strong fundamental performance from dividend-growing companies creates a compelling setup. For growth investors, the innovation happening in nuclear energy, space technology, and gene editing represents generational opportunities.

Stay nimble, stay disciplined, and remember - in markets like these, fortune favors the bold and the prepared.

Trade safe, trade smart, and ride the waves!

The Shark Water Trading Team

---

Disclaimer: This content is for educational and informational purposes only. Always do your own research and consult with a financial advisor before making investment decisions. Past performance does not guarantee future results.

Wolfspeed Update

 Wolfspeed Semiconductor and Bankruptcy: What’s Happening

Current Status

• Wolfspeed, a leading U.S. silicon carbide (SiC) semiconductor manufacturer, is preparing to file for Chapter 11 bankruptcy within weeks due to an unsustainable debt load of around $6.5 billion.

• The company’s stock has collapsed, dropping over 70% in a single day after reports of the impending bankruptcy, and now trades below $1 per share, down from a peak of $140 in 2021.

Key Issues

• Wolfspeed’s financial troubles stem from:

• Heavy debt from building new manufacturing facilities in North Carolina and New York.

• Delays in receiving $750 million in federal CHIPS Act funding, which is contingent on refinancing existing debt.

• Slowing demand for SiC chips in electric vehicles and industrial markets, plus intense price competition from Chinese rivals.

• Operational delays and underutilization at new plants, leading to significant losses and layoffs (about 25% of workforce cut since late 2023).

Bankruptcy Plan

• Wolfspeed is pursuing a “prepackaged” Chapter 11 bankruptcy, aiming to reorganize its debt with the support of key creditors like Apollo Global and Renesas Electronics.

• The company rejected multiple out-of-court restructuring offers, including proposals for debt-to-equity swaps by major lenders.

Leadership Changes

• The CEO and CFO have both recently been replaced as part of efforts to stabilize the company.

Outlook

• Wolfspeed’s bankruptcy is intended to allow the company to continue operating while restructuring its finances, not to liquidate.

• The company still holds a leading share in the SiC substrate market but faces mounting pressure from global competitors and uncertain federal support.

ELF Beauty: The $55 to $90+ Rocket Ship That Should Have You Retiring

If you listened to our previous calls around $55, you're looking at 60%+ gains and a potential early retirement fund.

---

What a ride it's been for ELF Beauty (NYSE: ELF) shareholders! As we write this on May 29th, 2025, the stock is trading at $90.50, representing a stunning +49.89% gain in just the past month alone. But here's the kicker – if you were paying attention to our previous analysis when we flagged this beauty disruptor around the $55 mark, you're sitting on gains that could literally fund your early retirement.

The Meteoric Numbers That Tell the Story

Let's break down the financial fireworks that have sent ELF into the stratosphere:

Recent Stock Performance:

• Current price: $90.50 (+9.28% in past 24 hours)
• Monthly surge: +49.89%
• Weekly gain: +15.50%
• 52-week range: $49.40 - $219.77

But the real story isn't just in the stock price – it's in the blockbuster business fundamentals that are driving this rocket ship to new heights.

The Billion-Dollar Catalyst: Rhode Acquisition

On May 28th, 2025, ELF dropped a bombshell that sent shares soaring +25% in a single day. The company announced its acquisition of Hailey Bieber's Rhode skincare brand for $1 billion – and this isn't just any celebrity beauty deal.

Why This Deal is Pure Gold:

• Rhode generated $212 million in net sales in just three years with only 10 products
• Rhode was the #1 skincare brand in earned media value (EMV) in 2024, with 367% year-over-year growth
• The brand more than doubled its consumer base over the past year
• Partnership with Sephora launching across North America and UK this year

As ELF CEO Tarang Amin put it: "I've been in the consumer space 34 years, and I've been blown away by seeing this brand over time. In less than three years, they've gone from zero to $212 million in net sales, direct-to-consumer only, with only 10 products. I didn't think that was possible."

The Earnings Beat That Exceeded All Expectations

ELF's Q4 2025 earnings report wasn't just good – it was spectacular:

Key Financial Highlights:

• Q4 revenue: $332.6 million
• Full year revenue: $1.31 billion
• Annual sales growth: 28% (fastest pace of any large beauty company)
• International sales exploded 66% year-over-year

Even more impressive, ELF's consensus earnings forecast from 11 analysts was $0.57 per share, and the company has been consistently beating expectations while expanding globally at breakneck speed.

Remember Our $55 Call? Here's Your Retirement Math

For those who've been following our analysis since we first highlighted ELF around the $55 mark, let's do some quick retirement math:

The Numbers Don't Lie:

• Entry point: ~$55
• Current price: $90.50
• Gain: 64.5%
• Analyst price target: $116.88 (additional 29% upside)

Real-World Example:

• $10,000 investment at $55 → $16,450 today
• $50,000 investment at $55 → $82,250 today
• $100,000 investment at $55 → $164,500 today

If analysts are right about the $116.88 target, that $100K investment could be worth $212,500 – more than doubling your money in less than a year.

Why This Isn't Just Another Beauty Stock

ELF isn't your typical cosmetics company. It's a digital-first disruptor that has cracked the code on Gen Z and Gen Alpha consumers:

The Disruption Playbook:

• Multi-generational appeal: #1 brand among Gen Z and most purchased brand among Gen Alpha and millennials
• Viral marketing that turns products into social media phenomena
• Value-oriented "dupes" of high-end products at accessible prices
• Aggressive international expansion (Netherlands, Belgium launches in 2025)

The Rhode Synergy: "What we saw in Rhode was another like-minded disruptor. I see Hailey as much more than a celebrity, she is one of the most thoughtful founders I've ever met." – Tarang Amin, ELF CEO

The Market is Taking Notice

Wall Street analysts are bullish, and for good reason:

• Goldman Sachs sees the Rhode deal "as a strategic positive as it further expands ELF into skincare with a prestige brand, and diversifies its customer base"
• Analyst estimates range from $70 to $120 per share
• Market cap: $5.17 billion and growing

The Retirement Reality Check

Look, we're not saying you should quit your day job based on one stock pick. But if you've been riding the ELF train from our $55 call, you're experiencing the kind of gains that can fundamentally change your financial trajectory.

The beauty of this play:

1. We called it early when the stock was undervalued
2. The fundamentals delivered with explosive growth and smart acquisitions
3. The runway is massive with international expansion and the Rhode integration
4. The trend is your friend with Gen Z/Alpha driving sustained demand

What's Next for ELF?

The Rhode acquisition isn't just about adding a celebrity brand – it's about strategic expansion into the prestige skincare market while maintaining ELF's accessible positioning. With analyst projections of revenue reaching $277.3 million by 2028 and continued international growth, this could be just the beginning.

Key catalysts ahead:

• Rhode integration and Sephora launch
• European expansion into Netherlands and Belgium
• Continued market share gains in core demographics
• Potential for additional strategic acquisitions

The Bottom Line

If you traded this right from our $55 call, you're not just looking at impressive gains – you're looking at life-changing returns. ELF Beauty has proven that it's not just another cosmetics company; it's a generational disruptor that has successfully navigated market challenges while positioning itself for explosive growth.

For those still on the sidelines, the current price of $90.50 might still represent value, with forecasts suggesting potential upside to $116.88. But remember – the easy money was made by those who recognized the opportunity early.

To our readers who followed our $55 analysis: Congratulations. You didn't just pick a winner – you picked a retirement accelerator.

---

Disclaimer: This analysis is for informational purposes only and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider your risk tolerance before making investment decisions.

A Nuclear Stock Short